Latest Conference Articles

September 29th 2023, 10:27pm

International Myeloma Society Annual Meeting

The EZH2 inhibitor tazemetostat may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.

September 29th 2023, 9:28pm

International Myeloma Society Annual Meeting

The combination of iberdomide plus bortezomib and dexamethasone produced deep responses with a manageable toxicity profile in patients with transplant-ineligible, newly diagnosed multiple myeloma, according to data from the phase 1/2 CC-220-MM-001 trial presented at the 2023 International Myeloma Society Annual Meeting.

September 29th 2023, 8:51pm

International Myeloma Society Annual Meeting

Treatment with teclistamab led to responses in patients with relapsed/refractory multiple myeloma, including those previously exposed to anti-BCMA therapies.

September 29th 2023, 8:50pm

International Myeloma Society Annual Meeting

Forimtamig monotherapy generated high overall response rates and durable responses in all subgroups of patients with relapsed/refractory multiple myeloma enrolled in a phase 1a dose-escalation trial.

September 29th 2023, 6:59pm

International Myeloma Society Annual Meeting

Although quadruplet combination regimens featuring daratumumab demonstrated consistent efficacy in the treatment of patients with newly diagnosed multiple myeloma, certain prognostic factors were associated with early relapse, according to data from a retrospective analysis presented at the 2023 International Myeloma Society Annual Meeting.

September 29th 2023, 6:35pm

International Myeloma Society Annual Meeting

Treatment with teclistamab-cqyv in real-world patients with relapsed/refractory multiple myeloma elicited similar efficacy results and a comparable safety profile to findings from the phase 1/2 Majes-TEC-1 trial.

September 29th 2023, 6:02pm

International Myeloma Society Annual Meeting

Induction daratumumab, carfilzomib, lenalidomide, and dexamethasone followed by consolidation double transplant sustained efficacy and safety in patients with high-risk, newly diagnosed multiple myeloma.

September 29th 2023, 3:10pm

International Myeloma Society Annual Meeting

Joshua Richter, MD, discusses findings from the phase 1/2 LINKER-MM1 trial (NCT03761108) in multiple myeloma.

September 29th 2023, 3:10pm

International Myeloma Society Annual Meeting

Shonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.

September 29th 2023, 2:15pm

International Myeloma Society Annual Meeting

Whole-genome sequencing of patients with multiple myeloma revealed that sequential immunotherapy was linked with antigen loss associated with treatment resistance and disease relapse.

September 28th 2023, 9:20pm

International Myeloma Society Annual Meeting

Treatment with the combination of pomalidomide, bortezomib, and dexamethasone conferred a small, statistically nonsignificant overall survival benefit compared with bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma.

September 28th 2023, 8:57pm

International Myeloma Society Annual Meeting

Mezigdomide in combination with either bortezomib and dexamethasone or carfilzomib and dexamethasone showed encouraging responses across multiple dose levels in patients with relapsed/refractory multiple myeloma.

September 28th 2023, 6:55pm

International Myeloma Society Annual Meeting

Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.

September 28th 2023, 6:55pm

International Myeloma Society Annual Meeting

Overall response rates with bispecific antibody monotherapy in patients with extramedullary relapsed/refractory multiple myeloma were lower than ORRs observed across all patients with relapsed/refractory multiple myeloma included in a systematic review evaluating the efficacy of this class of agents in this difficult-to-treat population.

September 28th 2023, 4:55pm

International Myeloma Society Annual Meeting

Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores in patients with multiple myeloma receiving systemic treatment.

September 28th 2023, 4:14pm

International Myeloma Society Annual Meeting

Meral Beksac, MD, discusses overall survival data from the phase 3 OPTIMISMM trial in relapsed/refractory multiple myeloma.

September 28th 2023, 3:12pm

International Myeloma Society Annual Meeting

Lisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.

September 27th 2023, 5:30pm

International Myeloma Society Annual Meeting

Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

September 25th 2023, 4:40pm

The smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.

September 20th 2023, 8:00pm

International Liver Cancer Association Annual Conference

Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.